Perbandingan Disease-Free Survival dan Overall Survival pada Pasien Kanker Payudara Stadium Dini yang Mendapatkan Terapi Adjuvan dan Tanpa Terapi Adjuvan: Systematic Literature Review
DOI:
https://doi.org/10.67096/medis.v1i3.495Keywords:
kanker payudara stadium dini, terapi adjuvan, disease-free survival, overall survival, tinjauan sistematisAbstract
Latar Belakang: Terapi adjuvan pada kanker payudara stadium dini bertujuan menurunkan risiko kekambuhan dan kematian, namun manfaatnya berbeda menurut risiko klinis, status reseptor, genomik tumor, dan usia pasien. Objektif: Membandingkan disease-free survival dan overall survival pada pasien kanker payudara stadium dini yang mendapatkan terapi adjuvan dengan pasien tanpa adjuvan, observasi, plasebo, atau strategi de-eskalasi. Metode: Artikel ini disusun sebagai tinjauan literatur sistematis berbasis PICO. Populasi adalah pasien kanker payudara stadium dini atau operabel non-metastatik. Intervensi mencakup kemoterapi, terapi endokrin, radioterapi, terapi target, dan imunoterapi adjuvan. Komparator adalah tanpa adjuvan, observasi, plasebo, atau de-eskalasi terapi. Outcome utama adalah disease-free survival dan overall survival. Tiga puluh artikel jurnal dipilih sebagai sumber sintesis. Hasil: Bukti menunjukkan bahwa terapi adjuvan memperbaiki disease-free survival pada pasien berisiko sedang-tinggi, terutama pada kanker HER2-positif, triple-negative, mutasi BRCA, dan HR-positif risiko tinggi. Sebaliknya, pasien risiko rendah berdasarkan profil klinis-genomik dapat menghindari sebagian terapi tanpa penurunan overall survival yang bermakna. Kesimpulan: Keputusan adjuvan tidak boleh dibuat hanya berdasarkan stadium. Stratifikasi biologis dan risiko kekambuhan menentukan keseimbangan manfaat, toksisitas, dan overtreatment.
References
Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. doi:10.1136/bmj.n71.
2. Campbell M, McKenzie JE, Sowden A, et al. Synthesis without meta-analysis (SWiM) in systematic reviews: reporting guideline. BMJ. 2020;368:l6890. doi:10.1136/bmj.l6890.
3. Burstein HJ, Curigliano G, Thurlimann B, et al. Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021. Ann Oncol. 2021;32(10):1216-1235. doi:10.1016/j.annonc.2021.06.023.
4. Early Breast Cancer Trialists' Collaborative Group. Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37,298 women with early breast cancer in 26 randomized trials. Lancet. 2019;393(10179):1440-1452. doi:10.1016/S0140-6736(18)33137-4.
5. Early Breast Cancer Trialists' Collaborative Group. Anthracycline-containing and taxane-containing chemotherapy for early-stage operable breast cancer: a patient-level meta-analysis of 100,000 women from 86 randomized trials. Lancet. 2023;401(10384):1277-1292. doi:10.1016/S0140-6736(23)00285-4.
6. Sparano JA, Gray RJ, Makower DF, et al. Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer. N Engl J Med. 2018;379(2):111-121. doi:10.1056/NEJMoa1804710.
7. Sparano JA, Gray RJ, Ravdin PM, et al. Clinical and genomic risk to guide the use of adjuvant therapy for breast cancer. N Engl J Med. 2019;380(25):2395-2405. doi:10.1056/NEJMoa1904819.
8. Kalinsky K, Barlow WE, Gralow JR, et al. 21-Gene assay to inform chemotherapy benefit in node-positive breast cancer. N Engl J Med. 2021;385(25):2336-2347. doi:10.1056/NEJMoa2108873.
9. Cardoso F, van't Veer LJ, Bogaerts J, et al. 70-Gene signature as an aid to treatment decisions in early-stage breast cancer. N Engl J Med. 2016;375(8):717-729. doi:10.1056/NEJMoa1602253.
10. Piccart M, van't Veer LJ, Poncet C, et al. 70-gene signature as an aid for treatment decisions in early breast cancer: updated results of the phase 3 MINDACT trial with 8.7 years follow-up. Lancet Oncol. 2021;22(4):476-488. doi:10.1016/S1470-2045(21)00007-3.
11. Francis PA, Regan MM, Fleming GF, et al. Adjuvant ovarian suppression in premenopausal breast cancer. N Engl J Med. 2015;372(5):436-446. doi:10.1056/NEJMoa1412379.
12. Francis PA, Pagani O, Fleming GF, et al. Tailoring adjuvant endocrine therapy for premenopausal breast cancer. N Engl J Med. 2018;379(2):122-137. doi:10.1056/NEJMoa1803164.
13. Davies C, Pan H, Godwin J, et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of estrogen receptor-positive breast cancer: ATLAS, a randomized trial. Lancet. 2013;381(9869):805-816. doi:10.1016/S0140-6736(12)61963-1.
14. Goss PE, Ingle JN, Pritchard KI, et al. Extending aromatase-inhibitor adjuvant therapy to 10 years. N Engl J Med. 2016;375(3):209-219. doi:10.1056/NEJMoa1604700.
15. Gnant M, Fitzal F, Rinnerthaler G, et al. Duration of adjuvant aromatase-inhibitor therapy in postmenopausal breast cancer. N Engl J Med. 2021;385(5):395-405. doi:10.1056/NEJMoa2104162.
16. Kunkler IH, Williams LJ, Jack WJL, Cameron DA, Dixon JM; PRIME II investigators. Breast-conserving surgery with or without irradiation in early breast cancer. N Engl J Med. 2023;388(7):585-594. doi:10.1056/NEJMoa2207586.
17. Whelan TJ, Smith S, Nielsen TO, et al. Omitting radiotherapy after breast-conserving surgery in luminal A breast cancer. N Engl J Med. 2023;389(7):612-619. doi:10.1056/NEJMoa2302344.
18. Hughes KS, Schnaper LA, Bellon JR, et al. Lumpectomy plus tamoxifen with or without irradiation in women age 70 years or older with early breast cancer: long-term follow-up of CALGB 9343. J Clin Oncol. 2013;31(19):2382-2387. doi:10.1200/JCO.2012.45.2615.
19. Whelan TJ, Olivotto IA, Parulekar WR, et al. Regional nodal irradiation in early-stage breast cancer. N Engl J Med. 2015;373(4):307-316. doi:10.1056/NEJMoa1415340.
20. Poortmans PM, Collette S, Kirkove C, et al. Internal mammary and medial supraclavicular irradiation in breast cancer. N Engl J Med. 2015;373(4):317-327. doi:10.1056/NEJMoa1415369.
21. Early Breast Cancer Trialists' Collaborative Group, Darby S, McGale P, Correa C, et al. Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomized trials. Lancet. 2011;378(9804):1707-1716. doi:10.1016/S0140-6736(11)61629-2.
22. Early Breast Cancer Trialists' Collaborative Group, McGale P, Taylor C, Correa C, et al. Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8,135 women in 22 randomized trials. Lancet. 2014;383(9935):2127-2135. doi:10.1016/S0140-6736(14)60488-8.
23. Johnston SRD, Harbeck N, Hegg R, et al. Abemaciclib combined with endocrine therapy for the adjuvant treatment of HR-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE). J Clin Oncol. 2020;38(34):3987-3998. doi:10.1200/JCO.20.02514.
24. Johnston SRD, Toi M, O'Shaughnessy J, et al. Abemaciclib plus endocrine therapy for HR-positive, HER2-negative, node-positive, high-risk early breast cancer: updated results from monarchE. Lancet Oncol. 2023;24(1):77-90. doi:10.1016/S1470-2045(22)00694-5.
25. Slamon DJ, Stroyakovskiy D, Yardley DA, et al. Ribociclib and endocrine therapy as adjuvant treatment in patients with HR-positive, HER2-negative early breast cancer. N Engl J Med. 2024;390(12):1080-1091. doi:10.1056/NEJMoa2305488.
26. Mayer EL, Dueck AC, Martin M, et al. Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 2021;22(2):212-222. doi:10.1016/S1470-2045(20)30642-2.
27. von Minckwitz G, Huang CS, Mano MS, et al. Trastuzumab emtansine for residual invasive HER2-positive breast cancer. N Engl J Med. 2019;380(7):617-628. doi:10.1056/NEJMoa1814017.
28. Tutt ANJ, Garber JE, Kaufman B, et al. Adjuvant olaparib for patients with BRCA1- or BRCA2-mutated breast cancer. N Engl J Med. 2021;384(25):2394-2405. doi:10.1056/NEJMoa2105215.
29. Geyer CE Jr, Garber JE, Gelber RD, et al. Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk early breast cancer. Ann Oncol. 2022;33(12):1250-1268. doi:10.1016/j.annonc.2022.09.159.
30. Schmid P, Cortes J, Dent R, et al. Event-free survival with pembrolizumab in early triple-negative breast cancer. N Engl J Med. 2022;386(6):556-567. doi:10.1056/NEJMoa2112651.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Galih Cahya Wijayanti (Author)

This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.






